secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K/A
Filed at:   2021-09-22T23:59:59+00:00
Accession:  0001493152-21-023317
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus discloses CMO separation terms: $454K severance, option extension to June 2023
--------------------------------------------------------------------------------

- Barbara White resigned as CMO; last day Sept 17, 2021.
- Severance includes base salary continuation of $454,400 over 12 months.
- Company will reimburse COBRA premiums for 12 months.
- Vested stock option exercise period extended to June 17, 2023.
- Separation agreement includes general release, cooperation, and non-disclosure obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000149315221023317/0001493152-21-023317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000149315221023317/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-023317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer